Literature DB >> 18404296

A preoperative decolonization protocol for staphylococcus aureus prevents orthopaedic infections.

Nalini Rao1, Barbara Cannella, Lawrence S Crossett, A J Yates, Richard McGough.   

Abstract

UNLABELLED: Staphylococcus aureus (S. aureus) is an independent risk factor for orthopaedic surgical site infection (SSI). To determine whether a preoperative decolonization protocol reduces S. aureus SSIs, we conducted a prospective observational study of patients undergoing elective total joint arthroplasty (TJA) at our institution, with two control groups. The concurrent control group comprised patients of surgeons who did not participate in the intervention study. The preintervention control group comprised patients of participating surgeons who had undergone elective TJA during the year before the study. Patients in the intervention group were screened preoperatively for S. aureus by nasal swab cultures. S. aureus carriers were decolonized with mupirocin ointment to the nares twice daily and chlorhexidine bath once daily for 5 days before surgery. All 164 of 636 participants (26%) who tested positive completed the decolonization protocol without adverse events and had no postoperative S. aureus SSIs at 1-year followup. In contrast, 1330 concurrent control patients had 12 S. aureus infections. If these infections had occurred in the 26% of patients expected to be nasal carriers of S. aureus at a given time, the infection rate would have been 3.5% (12 of 345) in the control group. In addition, the overall infection rate of the participating surgeons, including nonstaphylococcal infections, decreased from 2.6% during the preintervention period to 1.5% during the intervention period, translating to an adjusted economic gain of $231,741 for the hospital. The data suggest a preoperative decolonization protocol reduces S. aureus SSIs in patients undergoing TJA. LEVEL OF EVIDENCE: Level II, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404296      PMCID: PMC2384036          DOI: 10.1007/s11999-008-0225-4

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  32 in total

1.  Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery.

Authors:  M D Kalmeijer; E van Nieuwland-Bollen; D Bogaers-Hofman; G A de Baere
Journal:  Infect Control Hosp Epidemiol       Date:  2000-05       Impact factor: 3.254

2.  Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization.

Authors:  Andrew E Simor; Elizabeth Phillips; Allison McGeer; Ana Konvalinka; Mark Loeb; H Rosalyn Devlin; Alex Kiss
Journal:  Clin Infect Dis       Date:  2006-12-14       Impact factor: 9.079

3.  The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost.

Authors:  James D Whitehouse; N Deborah Friedman; Kathryn B Kirkland; William J Richardson; Daniel J Sexton
Journal:  Infect Control Hosp Epidemiol       Date:  2002-04       Impact factor: 3.254

4.  Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics.

Authors:  G E Cimochowski; M D Harostock; R Brown; M Bernardi; N Alonzo; K Coyle
Journal:  Ann Thorac Surg       Date:  2001-05       Impact factor: 4.330

5.  BBL CHROMagar Staph aureus is superior to mannitol salt for detection of Staphylococcus aureus in complex mixed infections.

Authors:  Holly A D'Souza; Ellen Jo Baron
Journal:  Am J Clin Pathol       Date:  2005-06       Impact factor: 2.493

6.  Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance.

Authors:  A Upton; S Lang; H Heffernan
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

7.  Rates and outcomes of primary and revision total hip replacement in the United States medicare population.

Authors:  Nizar N Mahomed; Jane A Barrett; Jeffrey N Katz; Charlotte B Phillips; Elena Losina; Robert A Lew; Edward Guadagnoli; William H Harris; Robert Poss; John A Baron
Journal:  J Bone Joint Surg Am       Date:  2003-01       Impact factor: 5.284

8.  Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study.

Authors:  M D Kalmeijer; H Coertjens; P M van Nieuwland-Bollen; D Bogaers-Hofman; G A J de Baere; A Stuurman; A van Belkum; J A J W Kluytmans
Journal:  Clin Infect Dis       Date:  2002-07-15       Impact factor: 9.079

9.  Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.

Authors:  Trish M Perl; Joseph J Cullen; Richard P Wenzel; M Bridget Zimmerman; Michael A Pfaller; Deborah Sheppard; Jennifer Twombley; Pamela P French; Loreen A Herwaldt
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

10.  Impact of treating Staphylococcus aureus nasal carriers on wound infections in cardiac surgery.

Authors:  A Konvalinka; L Errett; I W Fong
Journal:  J Hosp Infect       Date:  2006-08-23       Impact factor: 3.926

View more
  44 in total

1.  Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis.

Authors:  Karen E Beenken; James K Smith; Robert A Skinner; Sandra G Mclaren; William Bellamy; M Johannes Gruenwald; Horace J Spencer; Jessica A Jennings; Warren O Haggard; Mark S Smeltzer
Journal:  J Biomater Appl       Date:  2014-05-21       Impact factor: 2.646

2.  Prevalence of MRSA colonization in an adult urban Indian population undergoing orthopaedic surgery.

Authors:  Sanjay Agarwala; Dnyanesh Lad; Vikas Agashe; Anshul Sobti
Journal:  J Clin Orthop Trauma       Date:  2015-09-11

3.  Evidence that intraspecific trait variation among nasal bacteria shapes the distribution of Staphylococcus aureus.

Authors:  Ben Libberton; Rosanna E Coates; Michael A Brockhurst; Malcolm J Horsburgh
Journal:  Infect Immun       Date:  2014-06-30       Impact factor: 3.441

Review 4.  Antibacterial Prophylaxis for Surgical Site Infection in the Elderly: Practical Application.

Authors:  Maria Adriana Cataldo; Guido Granata; Nicola Petrosillo
Journal:  Drugs Aging       Date:  2017-07       Impact factor: 3.923

5.  What is the prevalence of MRSA colonization in elective spine cases?

Authors:  Antonia F Chen; Srinivas Chivukula; Lloydine J Jacobs; Matthew W Tetreault; Joon Y Lee
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

6.  Sterility of the personal protection system in total joint arthroplasty.

Authors:  Kenneth A Kearns; Dan Witmer; Junaid Makda; Javad Parvizi; Donald Jungkind
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

7.  Human prosthetic joint infections are associated with myeloid-derived suppressor cells (MDSCs): Implications for infection persistence.

Authors:  Cortney E Heim; Debbie Vidlak; Jessica Odvody; Curtis W Hartman; Kevin L Garvin; Tammy Kielian
Journal:  J Orthop Res       Date:  2017-12-05       Impact factor: 3.494

Review 8.  [Antibiotic prophylaxis in primary and revision hip arthroplasty: what is the evidence?].

Authors:  G Gradl; C Horn; L K L Postl; T Miethke; H Gollwitzer
Journal:  Orthopade       Date:  2011-06       Impact factor: 1.087

9.  A Longitudinal Study of S. aureus Infection in a National Cohort of Surgical Patients.

Authors:  William J O'Brien; Kalpana Gupta; Kamal M F Itani
Journal:  Open Forum Infect Dis       Date:  2019-08-13       Impact factor: 3.835

10.  IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infection.

Authors:  Cortney E Heim; Debbie Vidlak; Tyler D Scherr; Curtis W Hartman; Kevin L Garvin; Tammy Kielian
Journal:  J Immunol       Date:  2015-03-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.